The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Abstract
Understanding the mechanism of action of PARP inhibitors is key to optimizing their clinical use and effectiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Self-citationDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Self-citation53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Self-citationRepair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationGelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Fong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Self-citationRottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956
Self-citationHomologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015) · Nature · doi:10.1038/nature14184 · Cited by 903
Temozolomide: Mechanisms of Action, Repair and Resistance
Zhang, J., F.G. Stevens, M., & D. Bradshaw, T. (2012) · Current Molecular Pharmacology · doi:10.2174/1874467211205010102 · Cited by 885
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 856
A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription
Ju, B.-G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., & Rosenfeld, M. G. (2006) · Science · doi:10.1126/science.1127196 · Cited by 840
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Self-citationMammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Mateos-Gomez, P. A., Gong, F., Nair, N., Miller, K. M., Lazzerini-Denchi, E., & Sfeir, A. (2015) · Nature · doi:10.1038/nature14157 · Cited by 765
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756
Self-citationActivity-Induced DNA Breaks Govern the Expression of Neuronal Early-Response Genes
Madabhushi, R., Gao, F., Pfenning, A. R., Pan, L., Yamakawa, S., Seo, J., Rueda, R., Phan, T. X., Yamakawa, H., Pao, P.-C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.032 · Cited by 700
Menissier de Murcia, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 627
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination
Bryant, H. E., Petermann, E., Schultz, N., Jemth, A., Loseva, O., Issaeva, N., Johansson, F., Fernandez, S., McGlynn, P., & Helleday, T. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.206 · Cited by 602
Poly(ADP-ribose)–Dependent Regulation of DNA Repair by the Chromatin Remodeling Enzyme ALC1
Ahel, D., Hořejší, Z., Wiechens, N., Polo, S. E., Garcia-Wilson, E., Ahel, I., Flynn, H., Skehel, M., West, S. C., Jackson, S. P., et al. (2009) · Science · doi:10.1126/science.1177321 · Cited by 588
Topoisomerase I poisoning results in PARP-mediated replication fork reversal
Ray Chaudhuri, A., Hashimoto, Y., Herrador, R., Neelsen, K. J., Fachinetti, D., Bermejo, R., Cocito, A., Costanzo, V., & Lopes, M. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2258 · Cited by 499
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Jungmichel, S., Rosenthal, F., Altmeyer, M., Lukas, J., Hottiger, M. O., & Nielsen, M. L. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.026 · Cited by 373
ADP-ribosylation of proteins. Enzymology and biological significance.
Althaus, F. R., & Richter, C. (1987) · PubMed · Cited by 371
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond
Curtin, N. J., & Szabo, C. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.006 · Cited by 369
Strumberg, D., Pilon, A. A., Smith, M., Hickey, R., Malkas, L., & Pommier, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.11.3977-3987.2000 · Cited by 367
Self-citationPoly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Scott, C. L., Swisher, E. M., & Kaufmann, S. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8848 · Cited by 355
On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei
Chambon, P., Weill, J. D., Doly, J., Strosser, M. T., & Mandel, P. (1966) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(66)90502-x · Cited by 344
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Rulten, S. L., Fisher, A. E. O., Robert, I., Zuma, M. C., Rouleau, M., Ju, L., Poirier, G., Reina-San-Martin, B., & Caldecott, K. W. (2011) · Molecular Cell · doi:10.1016/j.molcel.2010.12.006 · Cited by 326
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Li, M., & Yu, X. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.025 · Cited by 321
Strom, C. E., Johansson, F., Uhlen, M., Szigyarto, C. A.-K., Erixon, K., & Helleday, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1241 · Cited by 296
Murai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293
Self-citationLangelier, M.-F., Riccio, A. A., & Pascal, J. M. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku474 · Cited by 265
Coleman, R. L., Sill, M. W., Bell-McGuinn, K., Aghajanian, C., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T. J., Chan, J. K., Chen, A., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 265
Barkauskaite, E., Jankevicius, G., & Ahel, I. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.05.007 · Cited by 247
Readers of poly(ADP-ribose): designed to be fit for purpose
Teloni, F., & Altmeyer, M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1383 · Cited by 247
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Nuclear ADP-Ribosylation and Its Role in Chromatin Plasticity, Cell Differentiation, and Epigenetics
Hottiger, M. O. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034506 · Cited by 229
PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
Das, B. B., Huang, S.-Y. N., Murai, J., Rehman, I., Amé, J.-C., Sengupta, S., Das, S. K., Majumdar, P., Zhang, H., Biard, D., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku088 · Cited by 225
Self-citationPlummer, R., Lorigan, P., Steven, N., Scott, L., Middleton, M. R., Wilson, R. H., Mulligan, E., Curtin, N., Wang, D., Dewji, R., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2113-1 · Cited by 179
Meder, V. S., Boeglin, M., de Murcia, G., & Schreiber, V. (2005) · Journal of Cell Science · doi:10.1242/jcs.01606 · Cited by 171
Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice
Farrés, J., Martín‐Caballero, J., Martínez, C. M., Lozano, J. J., Llacuna, L., Ampurdanés, C., Ruiz‐Herguido, C., Dantzer, F., Schreiber, V., Villunger, A., et al. (2013) · Blood · doi:10.1182/blood-2012-12-472845 · Cited by 162
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Zhao, H., Sifakis, E. G., Sumida, N., Millán-Ariño, L., Scholz, B. A., Svensson, J. P., Chen, X., Ronnegren, A. L., de Lima, C. D. M., Varnoosfaderani, F. S., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.07.019 · Cited by 147
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 142
Self-citationSynthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201250 · Cited by 136
Poly(ADP-ribose) Reactivates Stalled DNA Topoisomerase I and Induces DNA Strand Break Resealing
Malanga, M., & Althaus, F. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300437200 · Cited by 135
ADP-ribose polymers localized on Ctcf–Parp1–Dnmt1 complex prevent methylation of Ctcf target sites
Zampieri, M., Guastafierro, T., Calabrese, R., Ciccarone, F., Bacalini, M. G., Reale, A., Perilli, M., Passananti, C., & Caiafa, P. (2011) · Biochemical Journal · doi:10.1042/bj20111417 · Cited by 130
Henneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte‐Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500223112 · Cited by 129
CtIP-mediated resection is essential for viability and can operate independently of BRCA1
Polato, F., Callén, E., Wong, N., Faryabi, R. B., Bunting, S. F., Chen, H. T., Kozak, M., Kruhlak, M. J., Reczek, C. R., Lee, W., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131939 · Cited by 124
Protein ADP-ribosylation and the cellular response to DNA strand breaks
Caldecott, K. W. (2014) · DNA repair · doi:10.1016/j.dnarep.2014.03.021 · Cited by 122
Hay, T., Matthews, J. R., Pietzka, L., Lau, A., Cranston, A. N., Nygren, A. O. H., Douglas-Jones, A. G., Smith, G. C. M., Martin, N. M. B., O’Connor, M. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2388 · Cited by 114
Self-citationO’Connor, L. O., Rulten, S. L., Cranston, A. N., Odedra, R., Brown, H., Jaspers, J. E., Jones, L., Knights, C., Evers, B., Ting, A. K. T., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3240 · Cited by 96
Self-citationParrish, K. E., Cen, L., Murray, J., Calligaris, D., Kizilbash, S. H., Mittapalli, R. K., Carlson, B. L., Schroeder, M. A., Sludden, J., Boddy, A. V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0553 · Cited by 93
McNeish, I. A., Oza, A. M., Coleman, R. L., Scott, C. L., Konecny, G. E., Tinker, A. V., O’Malley, D. M., Brenton, J. D., Kristeleit, R. S., Bell‐McGuinn, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5508 · Cited by 93
PARP Inhibitors as P-glyoprotein Substrates
Lawlor, D., Martin, P., Busschots, S., Thery, J., O’Leary, J. J., Hennessy, B. T., & Stordal, B. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23952 · Cited by 88
Malanga, M., Czubaty, A., Girstun, A., Staroń, K., & Althaus, F. R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709495200 · Cited by 82
Fu, H., Martin, M. M., Regairaz, M., Huang, L., You, Y., Lin, C.-M., Ryan, M., Kim, R., Shimura, T., Pommier, Y. G., et al. (2015) · Nature Communications · doi:10.1038/ncomms7746 · Cited by 71
Self-citationGottschalk, A. J., Trivedi, R. D., Conaway, J. W., & Conaway, R. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.401141 · Cited by 61
Borin, T. F., Pongeluppi, R., Gelaleti, G. B., Leonel, C., Moschetta, M., Ferreira, L. C., & Zuccari, D. P. D. C. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p2-03-02 · Cited by 31
Kristeleit, R. S., Shapiro, G. I., LoRusso, P. M., Infante, J. R., Flynn, M., Patel, M. R., Tolaney, S. M., Hilton, J. F., Calvert, H., Giordano, H., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2585 · Cited by 24
Murai, J., & Pommier, Y. G. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-14151-0_10 · Cited by 21
Self-citationSolubilization of enzyme forming ADPR polymer from NAD
Shimizu, Y., Hasegawa, S., Fujimura, S., & Sügimura, T. (1967) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(67)90544-x · Cited by 16
Cited by
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Poly(ADP-ribose) polymerase inhibition: past, present and future
Curtin, N. J., & Szabo, C. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0076-6 · Cited by 556
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
Metadata
- Authors
- Pommier, Y., O’Connor, M. J., & de Bono, J.
- Venue
- Science Translational Medicine
- Published
- 2016-10-26
- Volume
- 8
- Issue
- 362
- Pages
- 362ps17-362ps17
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2539944286
- Cited by
- 739
- References
- 75
- FWCI
- 26.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.